Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
AIDS, Volume 19, No. 5, Year 2005
Notification
URL copied to clipboard!
Description
Backgound: A substantial number of patients start their first-line antiretroviral therapy at an advanced stage of an HIV-1 infection. Potential differences between specific drug regimens in antiviral efficacy and safety in these patients are of major importance. Methods: A post-hoc analysis within the randomized controlled 2NN trial comparing efficacy between regimes containing nevirapine (NVP), efavirenz (EFV), or both, in addition to stavudine and lamivudine. Primary outcome: risk of virologic failure in different strata of baseline CD4 T-lymphocyte counts and plasma HIV-1 RNA concentrations (pVL). Virologic failure: never reaching a pVL < 400 copies/ml, or a rebound to two consecutive values > 400 copies/ml. Results: The risk of virologic failure was increased at very low CD4 counts (< 25 × 106 cells/1) compared to CD4 counts > 200 × 106 cells/1 [hazard ratio (HR), 1.28; 95% confidence interval (CI), 0.93-1.77]. The same was seen for a pVL ≥ 100 000 copies/ml compared to a lower pVL (HR, 1.20; CI, 0.96-1.50). There were no statistically significant differences between NVP and EFV in risk of virologic failure within any of the CD4 or pVL strata, although EFV performed slightly better in the low CD4 stratum. The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count. Conclusions: Initial antiretroviral therapy including NVP or EFV is effective in patients with an advanced HIV-1 infection. A high baseline CD4 cell count is associated with the occurrence of rash in female patients using NVP. © 2005 Lippincott Williams & Wilkins.
Authors & Co-Authors
van Leth, Frank C.M.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Andrews, S.
South Africa, Cape Town
Brooklyn Medical Centre
Grinsztejn, Beatriz Gilda Jegerhorn
Brazil, Rio de Janeiro
Instituto Nacional de Infectologia Evandro Chagas Ini
Wilkins, Ed L.
United Kingdom, Manchester
North Manchester General Hospital
Lazanas, Marios C.
Greece, Athens
Hellenic Red Cross Hospital
Lange, Joep M.A.
Netherlands, Amsterdam
Universiteit Van Amsterdam
Montaner, Julio S.G.
Canada, Vancouver
The University of British Columbia
Statistics
Citations: 172
Authors: 7
Affiliations: 7
Identifiers
Doi:
10.1097/01.aids.0000162334.12815.5b
Research Areas
Environmental
Infectious Diseases
Study Design
Cohort Study
Participants Gender
Female